Helex
1 known investors
Helex develops gene editing-based therapeutics for genetic kidney diseases, with a focus on Autosomal Dominant Polycystic Kidney Disease. The company uses proprietary drug design and lipid nanoparticle delivery platforms to create treatments targeting chronic kidney disease.